VERACYTE, INC. reported first quarter ended March 31, 2026 results: revenue $139.1 million, net income $28.7 million.
“Key Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period in 2025: • Increased total revenue by 21% to $139.1 million and testing revenue by 26% to $135.1 million, driven by Decipher growth of 30% to $86.5 million and Afirma growth of 21% to $46.4 million. • Increased total volume by 17% to 47,615 tests and testing volume by 19% to 45,248 tests, driven by Decipher growth of 24% to approximately 28,000 tests and Afirma growth of 12% to approximately 17,200 tests. • Recorded GAAP net income of $28.7 million, or 20.6% of revenue, and delivered adjusted EBITDA of $42.8 million, or 30.8% of revenue.”
Brent Shafer was appointed as Director at VERACYTE, INC..
“the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.”
Tom Miller was appointed as Director at VERACYTE, INC..
“the Board appointed Tom Miller, Ph.D., and Brent Shafer to serve as directors of the Company, effective immediately.”
Earnings Releases
VERACYTE, INC. reported first quarter ended March 31, 2024 results: revenue $96.8 million, net income $1.9 million, EPS $0.02.
“EX-99.1 (EX-99.1 PRESS RELEASE 05.07.2024) --- PRESS RELEASE 05.07.2024 Document Exhibit 99.1 Veracyte Announces First Quarter 2024 Financial Results Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 7, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today”
Earnings Releases
VERACYTE, INC. reported financial results for the quarter and year ended December 31, 2023.
“On February 22, 2024, Veracyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report.”
John L. Bishop retired as Director at VERACYTE, INC..
“On February 7, 2024, John L. Bishop, a member of the Board of Directors (the “Board”) of Veracyte, Inc. (the “Company”), informed the Chair of the Board that he will retire at the end of his current term as director and not stand for reelection at the Company’s 2024 annual meeting of stockholders (the “2024 Annual Meeting”).”
M&A Transactions
VERACYTE, INC. completed an acquisition involving C2i Genomics, Inc. for $70.0 million (closed 2024-02-05).
“On February 5, 2024 (the “Closing Date”), Veracyte, Inc., a Delaware corporation (“Veracyte”), completed its previously announced acquisition of C2i Genomics, Inc., a Delaware corporation (“C2i Genomics”), for a purchase price of $70.0 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.